Annals of Hematology

, Volume 85, Issue 9, pp 631–632 | Cite as

Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab

  • Dimitri Flieger
  • Sabine Hainke
  • Wolfgang Fischbach
Letter to the Editor

References

  1. 1.
    Larson AM (2003) Liver disease in hereditary hemorrhagic telangiectasia. J Clin Gastroenterol 36:149–158PubMedCrossRefGoogle Scholar
  2. 2.
    Kindler HL, Karrison T, Lu C, Gandara DR, Stevenson J, Krug L, Janne P, Guterz TL, Stadler WM, Vokes EE (2005) A multicenter, double-blind, placebo-controlled randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo in patients (pts) with malignant mesothelioma (MM). Proc Am soc Clin Oncol 24:7019 (abstract)Google Scholar
  3. 3.
    Sadick H, Riedel F, Naim R, Goessler U, Hormann K, Hafner M, Lux A (2005) Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression. Haematologica 90:818–828PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Dimitri Flieger
    • 1
    • 2
  • Sabine Hainke
    • 1
  • Wolfgang Fischbach
    • 1
  1. 1.Department of Internal Medicine IIKlinikum AschaffenburgAschaffenburgGermany
  2. 2.I. Medizinische KlinikGP-Klinikum RüsselsheimRüsselsheimGermany

Personalised recommendations